8-K: Bausch + Lomb Unveils Ambitious Three-Year Growth Strategy

Bausch + Lomb outlined a comprehensive three-year strategy at its Investor Day, targeting above-market revenue growth, significant margin expansion, and a robust product pipeline with $7 billion in potential peak sales.

Summary

• Bausch + Lomb presented its three-year strategic plan (2025-2028) at its Investor Day, focusing on company transformation, profitable growth, and pipeline innovation.
• The company reaffirmed its previously announced guidance for the fiscal year ending December 31, 2025.
• Key financial targets include a 5-7% constant currency revenue CAGR through 2028 and an approximately 23% adjusted EBITDA (ex. Acq. IPR&D) margin in 2028, up from ~17% in FY25.
• Management expects double-digit adjusted annual earnings per share growth (ex. Acq. IPR&D) from 2026-2028 and approximately 50% adjusted cash flow from operations to adjusted EBITDA (ex. Acq. IPR&D) conversion in 2028.
• The company aims for net leverage of approximately 3.5x by the end of 2028 and targets an investment-grade rating in the long-term.
• A robust product pipeline with over 60 projects and more than 20 potential 'game-changers' is projected to generate approximately $7 billion in total peak sales, staggered based on launch dates.
• Pipeline innovations span Consumer, Pharmaceuticals, Surgical, and Contact Lens segments, addressing unmet needs in areas like AMD, dry eye, ocular surface pain, glaucoma, and myopia.

Sentiment

Score: 8

Explanation: The filing outlines a comprehensive and ambitious three-year strategic plan with aggressive financial targets for revenue growth, margin expansion, and EPS growth. The extensive and innovative product pipeline, including several potential 'first-in-class' therapies, suggests significant future value creation. Management's confident tone about transformation and execution further supports a strong positive sentiment.

Positives

• Targeting 5-7% constant currency revenue CAGR through 2028, indicating strong projected growth.
• Projecting significant Adjusted EBITDA (ex. Acq. IPR&D) margin expansion to ~23% in 2028, a 600 basis point increase from ~17% in FY25.
• Anticipating double-digit adjusted annual EPS growth (ex. Acq. IPR&D) from 2026-2028.
• Targeting approximately 50% adjusted cash flow from operations to adjusted EBITDA (ex. Acq. IPR&D) conversion in 2028, demonstrating strong cash generation.
• A robust product pipeline is expected to deliver approximately $7 billion in total projected peak sales.
• Reaffirmed 2025 guidance, providing stability and confidence in near-term performance.
• Broad-based growth expected across all business segments: Consumer (5-7% CC CAGR), Contact Lens (5-7% CC CAGR), Pharmaceuticals (5-7% CC CAGR), and Surgical (6-8% CC CAGR) through 2028.
• Focus on disruptive innovation, new capabilities in disease biology, advanced formulations, and material science, with over 60 R&D projects in the pipeline.
• Commitment to reducing net leverage to ~3.5x by the end of 2028 and targeting an investment-grade rating in the long-term.

Risks

• Studies for pipeline products may not produce successful results or demonstrate safety and efficacy in humans.
• Pre-clinical and clinical trials may be delayed, which could delay the launch of new products.
• Regulatory approval of products may be lengthy, costly, and ultimately unsuccessful.
• Products may not achieve anticipated levels of market acceptance due to various factors, including negative publicity or reputational harm.
• Competitive risks, such as competitors beating the company to market or developing new or better technologies.
• Potential supply interruptions with finished products or components thereof.
• Uncertainties regarding the proposed plan to separate the company into an independent, publicly traded company from Bausch Health Companies Inc. (BHC), including timing, terms, achievement of targeted debt leverage ratios, market conditions, and receipt of necessary approvals.
• Impact of any potential sales or dispositions of the company's common shares by BHC, including in connection with a foreclosure on pledged shares.
• Risks related to acquisitions and other business development transactions, including pending transactions not closing, not realizing expected benefits, and increased debt levels.
• Expected impact of tariffs imposed by the U.S. and counter-tariffs or other retaliatory measures, and disruptions to global supply chains.
• Risks and uncertainties caused by or relating to a potential recession and other adverse economic conditions (e.g., heightened inflation, interest rates, exchange rate fluctuations, trade protection measures, slower growth) which could adversely impact revenues, expenses, and margins.

Future Outlook

Bausch + Lomb projects above-market revenue growth and meaningful margin expansion through 2028, driven by a robust pipeline of innovative products across consumer, pharmaceutical, surgical, and contact lens segments. The company aims for double-digit adjusted EPS growth and a strong balance sheet, targeting an investment-grade rating long-term. The extensive pipeline, including several 'first-in-class' and 'game-changing' innovations, is expected to sustain growth well into the next decade.

Management Comments

• "Bausch + Lomb today is a fundamentally different company than it was just a few years ago. Weve reignited a sense of ownership and ambition across the organization to better serve patients, customers and consumers and deliver sustainable, profitable growth." Brent Saunders, Chairman and CEO.
• "Our roadmap to above-market growth and meaningful margin expansion is clear. Were driving P&L leverage and making smart investments in innovation and execution to ensure that every dollar contributes to long-term value creation for our shareholders." Sam Eldessouky, Executive Vice President and Chief Financial Officer.
• "Were pushing the boundaries of ocular science to transform how eye diseases – from common to complex – are understood, treated and ultimately prevented. Weve been bringing new products to market at a record pace, and our innovation engine is built to sustain growth well into the next decade." Yehia Hashad, MD, Executive Vice President, R&D and Chief Medical Officer.

Industry Context

The company is positioning itself to capitalize on growing global eye health markets, including rising prevalence of dry eye, impacts of digital lifestyles, and an aging population. It aims to outperform market growth in consumer, contact lens, pharmaceutical, and surgical segments by introducing differentiated products and addressing significant unmet needs. The filing highlights a lack of new material breakthroughs in the contact lens industry for over 25 years, which Bausch + Lomb aims to disrupt with its planned bioactive hyaluronic acid hydrogel lens. The company is also targeting complex diseases like AMD and glaucoma with novel therapeutic approaches.

Comparison to Industry Standards

• The company aims for "above-market revenue growth" and "meaningful margin expansion," indicating a strategy to exceed average industry performance.
• The contact lens pipeline includes a planned "first-of-its-kind bioactive hyaluronic acid hydrogel lens," which would be the first new contact lens material breakthrough in over 25 years.
• A potential first-in-class dual-action eye drop combining active ingredients of MIEBO and XIIDRA is expected to offer superior efficacy and tolerability compared to existing single-action dry eye treatments.
• A neurosensory-targeted therapy for ocular surface pain is under development, which would be the "first" to address this critical unmet need.
• A glaucoma medication under development is designed to be the "first to treat vision loss in addition to lowering intraocular pressure."
• ELIOS, an implant-free minimally invasive glaucoma surgery (MIGS) approach, is described as the "first clinically-validated excimer laser MIGS," with extensive clinical data and European approval.
• The PreserVision brand is highlighted as the "#1 Eye Vitamin Brand" with approximately 93% market share, and LUMIFY as the "#1 eye doctor recommended redness reliever," demonstrating strong market leadership in consumer eye health.

Legal Proceedings

• The company notes that 'litigation and other matters' are excluded from non-GAAP adjustments, and that companies in the industry often face litigation, but no specific new or ongoing legal proceedings are detailed in this filing.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through above-market growth, significant margin expansion, double-digit EPS growth, and a robust product pipeline. Commitment to reducing net leverage and targeting an investment-grade rating could enhance investor confidence.
• Patients/Customers/Consumers: Anticipated access to new, innovative eye health products and therapies designed to improve vision, address unmet medical needs, and enhance comfort across various conditions.
• Employees: Reinvention of company culture around accountability and innovation, with a focus on expanding R&D talent and capabilities.
• Creditors: Commitment to reducing net leverage to ~3.5x by the end of 2028 and targeting an investment-grade rating indicates improved financial health and reduced credit risk.

Next Steps

• Launch new PreserVision formulation (1H 2026).
• Launch preservative-free lipid-based Blink Triple Care (1H 2026).
• Initiate BL1332 Phase 2 POC (1H 2026).
• Initiate registration clinical study for myopia control lens in U.S. (1H 2026).
• Launch SeeLyra next-generation femtosecond laser (2H 2026).
• Launch ELIOS in U.S. (2H 2026).
• Anticipated clinical study data for dual-action eye drop (2H 2026).
• Anticipated readout of larger Phase 2 study for BL1107 (2H 2026).
• Anticipate development candidate for gene silencing (2H 2026).
• NDA Submission for Lumify + HA (1Q 2026).
• Launch new LUMIFY formulation (1H 2027).
• Launch enVista Beyond intraocular lens (2027).
• Enter development with precision medicine guided therapeutic for AMD/GA (2027).
• Launch bioactive hyaluronic acid hydrogel lens (2028).
• Launch SeeNova phaco and vitreoretinal platform (2028).
• Launch dual-action eye drop (2029).
• Launch cost-competitive daily disposable silicon hydrogel lens (2029).
• Launch premium silicon hydrogel offering (2029).
• Launch silicon hydrogel myopia control lens (2029).
• Launch first neurosensory-targeted therapy for ocular surface pain (~2030).
• Anticipate approval for first small molecule sustained release implant for GA (2030+).
• Launch glaucoma medication (~2031).
• Continue to drive commercial and operational excellence.
• Advance pipeline to deliver sustainable growth.
• Capacity expansion.
• Reduce net leverage to ~3.5x by end of 2028.
• Maintain framework for investment grade profile.
• Pursue disciplined M&A/BD&L opportunities.
• Strategic partnerships to advance innovation.

Key Dates

Recommendation

The company has outlined a compelling three-year strategic plan with ambitious financial targets, including above-market revenue growth (5-7% CAGR), substantial Adjusted EBITDA margin expansion (from ~17% to ~23%), and double-digit adjusted EPS growth. The robust product pipeline, with an estimated $7 billion in potential peak sales and several 'first-in-class' innovations across key eye health segments, provides a strong foundation for future growth. The commitment to reducing net leverage and achieving an investment-grade rating further strengthens the financial outlook. These factors collectively suggest a strong positive trajectory for the company, making it an attractive investment.

Keywords

Bausch + Lomb, BLCO, Eye Health, Financial Targets, Pipeline, Investor Day, Revenue Growth, EBITDA Margin, EPS Growth, Contact Lenses, Pharmaceuticals, Surgical, Consumer Health, Ocular Science, R&D, Innovation, Dry Eye, Glaucoma, AMD, Myopia